Vertigo Treatment Market By Type, By Treatment, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

PUBLISHED: September 1, 2022

PAGES: 310 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The global vertigo treatment market was valued at $1,258.33 million in 2021, and is projected to reach $1,938.47 million by 2031, registering a CAGR of 4.4% from 2022 to 2031.

A person with vertigo experiences the illusion that the items around him are moving when they are still. Sweating, nausea, vomiting, difficulty in walking, and loss of balance are common symptoms of the illness. The most common cause of vertigo is benign paroxysmal positional vertigo (BPPV). There are two types of vertigo, namely peripheral and central. For instance, peripheral vertigo is caused by a problem with vestibular system and due to motion sickness. Central vertigo is caused due to central nervous system injuries. Furthermore, the treatments for vertigo are prescribed depending upon the type and severity of symptoms. For instance, medications include anticholinergics, antihistamines, beta-blockers, and anticonvulsants.

The growth of the global vertigo treatment market is majorly driven by increase in prevalence of vertigo, rise in geriatric population as vertigo incidences increase with age, rise in awareness about inner ear problems, availability of vertigo medications, and initiatives taken by government to develop better healthcare infrastructure. For instance, according to National Library of Medicine, around 15%-20% adults are affected by vertigo every year. Moreover, rise in brain injuries, viral infections, and heart diseases contribute towards the market growth.

However, ignorance towards symptoms of vertigo, side effects associated with antivertigo medications, lack of standard tools for diagnosis in some regions, and high research and development costs hinders the market growth.

The vertigo treatment market is segmented into type, treatment, distribution channel, and region. By type, the market is categorized into peripheral vertigo and central vertigo. On the basis of treatment, the market is segregated into anticholinergics, antihistamines, and others. By distribution channel, the market is classified into hospital pharmacies, drug stores and retail pharmacies (prescription drugs and OTC drugs), and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global vertigo treatment market are Amneal Pharmaceuticals Ltd., AstraZeneca Plc., Epic Pharma, LLC, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ag, Intas Phrmaceuticals Ltd, Novartis Ag, Pfizer Inc.., Sanofi, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Ltd., and Viatris (Mylan N.V.).

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vertigo treatment market analysis from 2021 to 2031 to identify the prevailing vertigo treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vertigo treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vertigo treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Peripheral Vertigo
Central Vertigo

By Treatment

Anticholinergics
Antihistamines
Others

By Distribution channel

Hospital Pharmacies
Drug Stores Retail Pharmacies
- Prescription Type
- Prescription Drugs
- OTC Drugs
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- AstraZeneca plc.
- Endo Pharmaceuticals Inc
- Epic Pharma, LLC
- GlaxoSmithKline plc.
- Hoffmann-La Roche
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Ltd.
- Viatris (Mylan N.V.)
- Zydus Cadila

Product Code: A12485

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: VERTIGO TREATMENT MARKET, BY TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Peripheral Vertigo
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Central Vertigo
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country

CHAPTER 5: VERTIGO TREATMENT MARKET, BY TREATMENT

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Anticholinergics
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Antihistamines
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country

CHAPTER 6: VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Drug Stores & Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.3.4 Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
  - 6.3.4.1 Prescription Drugs Market size and forecast, by region
  - 6.3.4.2 OTC Drugs Market size and forecast, by region
6.4 Online Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: VERTIGO TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by Distribution channel
  - 7.2.4.1 North America Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Type
  - 7.2.5.1.2 Market size and forecast, by Treatment
  - 7.2.5.1.3 Market size and forecast, by Distribution channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Type
  - 7.2.5.2.2 Market size and forecast, by Treatment
  - 7.2.5.2.3 Market size and forecast, by Distribution channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Type
  - 7.2.5.3.2 Market size and forecast, by Treatment
  - 7.2.5.3.3 Market size and forecast, by Distribution channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by Distribution channel
  - 7.3.4.1 Europe Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Type
  - 7.3.5.1.2 Market size and forecast, by Treatment
  - 7.3.5.1.3 Market size and forecast, by Distribution channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Type
  - 7.3.5.2.2 Market size and forecast, by Treatment
  - 7.3.5.2.3 Market size and forecast, by Distribution channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Type
  - 7.3.5.3.2 Market size and forecast, by Treatment
  - 7.3.5.3.3 Market size and forecast, by Distribution channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Type
  - 7.3.5.4.2 Market size and forecast, by Treatment
  - 7.3.5.4.3 Market size and forecast, by Distribution channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Type
  - 7.3.5.5.2 Market size and forecast, by Treatment
  - 7.3.5.5.3 Market size and forecast, by Distribution channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Type
  - 7.3.5.6.2 Market size and forecast, by Treatment
  - 7.3.5.6.3 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
  - 7.4.4.1 Asia-Pacific Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Type
  - 7.4.5.1.2 Market size and forecast, by Treatment
  - 7.4.5.1.3 Market size and forecast, by Distribution channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Type
  - 7.4.5.2.2 Market size and forecast, by Treatment
  - 7.4.5.2.3 Market size and forecast, by Distribution channel
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Type
  - 7.4.5.3.2 Market size and forecast, by Treatment
  - 7.4.5.3.3 Market size and forecast, by Distribution channel
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Type
  - 7.4.5.4.2 Market size and forecast, by Treatment
  - 7.4.5.4.3 Market size and forecast, by Distribution channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Type
  - 7.4.5.5.2 Market size and forecast, by Treatment
  - 7.4.5.5.3 Market size and forecast, by Distribution channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Type
  - 7.4.5.6.2 Market size and forecast, by Treatment
  - 7.4.5.6.3 Market size and forecast, by Distribution channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by Distribution channel
  - 7.5.4.1 LAMEA Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Type
  - 7.5.5.1.2 Market size and forecast, by Treatment
  - 7.5.5.1.3 Market size and forecast, by Distribution channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Type
  - 7.5.5.2.2 Market size and forecast, by Treatment
  - 7.5.5.2.3 Market size and forecast, by Distribution channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Type
  - 7.5.5.3.2 Market size and forecast, by Treatment
  - 7.5.5.3.3 Market size and forecast, by Distribution channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Type
  - 7.5.5.4.2 Market size and forecast, by Treatment
  - 7.5.5.4.3 Market size and forecast, by Distribution channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 AstraZeneca plc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Endo Pharmaceuticals Inc
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Epic Pharma, LLC
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 GlaxoSmithKline plc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Hoffmann-La Roche
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Novartis AG
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Sanofi
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Sun Pharmaceutical Industries Ltd.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Viatris (Mylan N.V.)
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Zydus Cadila
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments

Product Code: A12485

LIST OF TABLES

TABLE 1. GLOBAL VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. VERTIGO TREATMENT MARKET SIZE, FOR PERIPHERAL VERTIGO, BY REGION, 2021-2031 ($MILLION)
TABLE 3. VERTIGO TREATMENT MARKET FOR PERIPHERAL VERTIGO, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. VERTIGO TREATMENT MARKET SIZE, FOR CENTRAL VERTIGO, BY REGION, 2021-2031 ($MILLION)
TABLE 5. VERTIGO TREATMENT MARKET FOR CENTRAL VERTIGO, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 7. VERTIGO TREATMENT MARKET SIZE, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. VERTIGO TREATMENT MARKET FOR ANTICHOLINERGICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. VERTIGO TREATMENT MARKET SIZE, FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. VERTIGO TREATMENT MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. VERTIGO TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. VERTIGO TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 14. VERTIGO TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 15. VERTIGO TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. VERTIGO TREATMENT MARKET SIZE, FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 17. VERTIGO TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 19. VERTIGO TREATMENT MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. VERTIGO TREATMENT MARKET, FOR OTC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 21. VERTIGO TREATMENT MARKET SIZE, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. VERTIGO TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. VERTIGO TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. U.S. VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 30. U.S. VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 31. U.S. VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 32. CANADA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 33. CANADA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 34. CANADA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 35. MEXICO VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 36. MEXICO VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 37. MEXICO VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. EUROPE VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 39. EUROPE VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 40. EUROPE VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. EUROPE DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 42. EUROPE VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. GERMANY VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. GERMANY VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 45. GERMANY VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. FRANCE VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 47. FRANCE VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 48. FRANCE VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. UK VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 50. UK VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 51. UK VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. ITALY VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 53. ITALY VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 54. ITALY VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. SPAIN VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 56. SPAIN VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 57. SPAIN VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. REST OF EUROPE VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 59. REST OF EUROPE VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 66. JAPAN VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 67. JAPAN VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 68. JAPAN VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. CHINA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 70. CHINA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 71. CHINA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. AUSTRALIA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 73. AUSTRALIA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 74. AUSTRALIA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. INDIA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 76. INDIA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 77. INDIA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. SOUTH KOREA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 79. SOUTH KOREA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 82. REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. LAMEA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 85. LAMEA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 86. LAMEA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. LAMEA DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 88. LAMEA VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 89. BRAZIL VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. BRAZIL VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 91. BRAZIL VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 92. SAUDI ARABIA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 93. SAUDI ARABIA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 95. SOUTH AFRICA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 96. SOUTH AFRICA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. REST OF LAMEA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 99. REST OF LAMEA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101.ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 102.ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 103.ASTRAZENECA PLC.: PRODUCT PORTFOLIO
TABLE 104.ASTRAZENECA PLC.: NET SALES,
TABLE 105.ASTRAZENECA PLC.: KEY STRATERGIES
TABLE 106.ENDO PHARMACEUTICALS INC: COMPANY SNAPSHOT
TABLE 107.ENDO PHARMACEUTICALS INC: OPERATING SEGMENTS
TABLE 108.ENDO PHARMACEUTICALS INC: PRODUCT PORTFOLIO
TABLE 109.ENDO PHARMACEUTICALS INC: NET SALES,
TABLE 110.ENDO PHARMACEUTICALS INC: KEY STRATERGIES
TABLE 111.EPIC PHARMA, LLC: COMPANY SNAPSHOT
TABLE 112.EPIC PHARMA, LLC: OPERATING SEGMENTS
TABLE 113.EPIC PHARMA, LLC: PRODUCT PORTFOLIO
TABLE 114.EPIC PHARMA, LLC: NET SALES,
TABLE 115.EPIC PHARMA, LLC: KEY STRATERGIES
TABLE 116.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 117.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 118.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 119.GLAXOSMITHKLINE PLC.: NET SALES,
TABLE 120.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 121.HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
TABLE 122.HOFFMANN-LA ROCHE: OPERATING SEGMENTS
TABLE 123.HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 124.HOFFMANN-LA ROCHE: NET SALES,
TABLE 125.HOFFMANN-LA ROCHE: KEY STRATERGIES
TABLE 126.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 127.NOVARTIS AG: OPERATING SEGMENTS
TABLE 128.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 129.NOVARTIS AG: NET SALES,
TABLE 130.NOVARTIS AG: KEY STRATERGIES
TABLE 131.PFIZER INC.: COMPANY SNAPSHOT
TABLE 132.PFIZER INC.: OPERATING SEGMENTS
TABLE 133.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 134.PFIZER INC.: NET SALES,
TABLE 135.PFIZER INC.: KEY STRATERGIES
TABLE 136.SANOFI: COMPANY SNAPSHOT
TABLE 137.SANOFI: OPERATING SEGMENTS
TABLE 138.SANOFI: PRODUCT PORTFOLIO
TABLE 139.SANOFI: NET SALES,
TABLE 140.SANOFI: KEY STRATERGIES
TABLE 141.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 142.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 143.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 144.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 145.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 146.TEVA PHARMACEUTICAL LTD.: COMPANY SNAPSHOT
TABLE 147.TEVA PHARMACEUTICAL LTD.: OPERATING SEGMENTS
TABLE 148.TEVA PHARMACEUTICAL LTD.: PRODUCT PORTFOLIO
TABLE 149.TEVA PHARMACEUTICAL LTD.: NET SALES,
TABLE 150.TEVA PHARMACEUTICAL LTD.: KEY STRATERGIES
TABLE 151.VIATRIS (MYLAN N.V.): COMPANY SNAPSHOT
TABLE 152.VIATRIS (MYLAN N.V.): OPERATING SEGMENTS
TABLE 153.VIATRIS (MYLAN N.V.): PRODUCT PORTFOLIO
TABLE 154.VIATRIS (MYLAN N.V.): NET SALES,
TABLE 155.VIATRIS (MYLAN N.V.): KEY STRATERGIES
TABLE 156.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 157.ZYDUS CADILA: OPERATING SEGMENTS
TABLE 158.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 159.ZYDUS CADILA: NET SALES,
TABLE 160.ZYDUS CADILA: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.VERTIGO TREATMENT MARKET SEGMENTATION
FIGURE 2.VERTIGO TREATMENT MARKET,2021-2031
FIGURE 3.VERTIGO TREATMENT MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.VERTIGO TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.VERTIGO TREATMENT MARKET,BY TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PERIPHERAL VERTIGO VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CENTRAL VERTIGO VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 15.VERTIGO TREATMENT MARKET,BY TREATMENT,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ANTICHOLINERGICS VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 19.VERTIGO TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS VERTIGO TREATMENT MARKET,2021-2031(%)
FIGURE 23.VERTIGO TREATMENT MARKET BY REGION,2021
FIGURE 24.U.S. VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 25.CANADA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 26.MEXICO VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 27.GERMANY VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 28.FRANCE VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 29.UK VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 30.ITALY VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 31.SPAIN VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 32.REST OF EUROPE VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 33.JAPAN VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 34.CHINA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 35.AUSTRALIA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 36.INDIA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 37.SOUTH KOREA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 38.REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 39.BRAZIL VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 40.SAUDI ARABIA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 41.SOUTH AFRICA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 42.REST OF LAMEA VERTIGO TREATMENT MARKET,2021-2031($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47.COMPETITIVE DASHBOARD
FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 49.ASTRAZENECA PLC..: NET SALES ,($MILLION)
FIGURE 50.ENDO PHARMACEUTICALS INC.: NET SALES ,($MILLION)
FIGURE 51.EPIC PHARMA, LLC.: NET SALES ,($MILLION)
FIGURE 52.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
FIGURE 53.HOFFMANN-LA ROCHE.: NET SALES ,($MILLION)
FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 55.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 56.SANOFI.: NET SALES ,($MILLION)
FIGURE 57.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
FIGURE 58.TEVA PHARMACEUTICAL LTD..: NET SALES ,($MILLION)
FIGURE 59.VIATRIS (MYLAN N.V.).: NET SALES ,($MILLION)
FIGURE 60.ZYDUS CADILA.: NET SALES ,($MILLION)